Complex mixture of neurotrophic-active peptide fragments that cross the blood-brain barrier. Delivers exogenous neurotrophic factor activity (BDNF-like, NGF-like). Anti-apoptotic in neurons, promotes neuroplasticity, reduces amyloid-β accumulation, modulates tau phosphorylation, and reduces oxidative stress.
Studies have administered: 5–30mL IV daily for acute conditions in published trials; 5mL IM in maintenance protocols
Multiple Alzheimer RCTs (Reisberg 2003, Panisset 2002): cognitive improvement vs placebo. Stroke: Cochrane review acknowledges evidence of benefit but quality concerns. TBI: strong human evidence base from Eastern European literature. Regulatory approved in 35+ countries.
Allergic reactions possible (porcine-derived protein); dizziness; agitation at high doses; contraindicated in epilepsy; generally well-tolerated in studies
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Cerebrolysin — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat